Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules

Koji Tamada, Lieping Chen

Research output: Contribution to journalArticle

Abstract

Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.

Original languageEnglish (US)
Pages (from-to)355-362
Number of pages8
JournalCancer Immunology Immunotherapy
Volume55
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Immunotherapy
Tumor Necrosis Factor-alpha
Neoplasms
Tumor Necrosis Factor Receptors
Genomics
Computational Biology
Therapeutics
Light

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. / Tamada, Koji; Chen, Lieping.

In: Cancer Immunology Immunotherapy, Vol. 55, No. 4, 04.2006, p. 355-362.

Research output: Contribution to journalArticle

@article{b85b4a37e0504ca29a303725ae11cfd5,
title = "Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules",
abstract = "Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.",
author = "Koji Tamada and Lieping Chen",
year = "2006",
month = "4",
doi = "10.1007/s00262-005-0081-y",
language = "English (US)",
volume = "55",
pages = "355--362",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules

AU - Tamada, Koji

AU - Chen, Lieping

PY - 2006/4

Y1 - 2006/4

N2 - Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.

AB - Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.

UR - http://www.scopus.com/inward/record.url?scp=30444442143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444442143&partnerID=8YFLogxK

U2 - 10.1007/s00262-005-0081-y

DO - 10.1007/s00262-005-0081-y

M3 - Article

C2 - 16187084

AN - SCOPUS:30444442143

VL - 55

SP - 355

EP - 362

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -